An experimental Covid-19 vaccine appears to offer strong protection in late-stage UK and South Africa studies, said manufacturer Novavax.
The protein-based vaccine candidate was shown to be 89.3 per cent effective at preventing coronavirus in participants in its Phase 3 clinical trial in the UK, which enrolled more than 15,000 people between 18-84, of which 27 per cent were older than 65, Novavax said.
“NVX-CoV2373 is the first vaccine to demonstrate not only high clinical efficacy against Covid-19 but also significant clinical efficacy against both the rapidly emerging UK and South Africa variants,” said Stanley Erck, the biotechnology firm’s president and chief executive.
The trial was carried out in conjunction with the UK Government’s Vaccine Taskforce, with its chairman Clive Dix saying in a statement: “These are spectacular results, and we are very pleased to have helped Novavax with the development of this vaccine.
“The efficacy shown against the emerging variants is also extremely encouraging. This is an incredible achievement that will ensure we can protect individuals in the UK and the rest of the world from this virus.”
Although the UK has 60 million doses on order, it will need to be approved by the Medicines and Healthcare products Regulatory Agency.
Good news that the @Novavax vaccine has proved effective in UK trials. Thank you to all the volunteers who made these results possible.
Our medicines regulator will now assess the vaccine, which will be made in Teesside. If approved, we have 60m doses on order.
— Boris Johnson (@BorisJohnson) January 28, 2021
UK Prime Minister Boris Johnson has said it is “good news” that the experimental coronavirus vaccine from Novavax appears to offer strong protection in late-stage UK and South Africa studies.
He tweeted: “Good news that the @Novavax vaccine has proved effective in UK trials. Thank you to all the volunteers who made these results possible.
“Our medicines regulator will now assess the vaccine, which will be made in Teesside. If approved, we have 60m doses on order.”
The UK Health Secretary Matt Hancock said the NHS stands ready to roll out the Novavax vaccine if it is approved by the medicines regulator.
He said: “This is positive news and, if approved by the medicines regulator, the Novavax vaccine will be a significant boost to our vaccination programme and another weapon in our arsenal to beat this awful virus.”
Vaccines Minister Nadhim Zahawi added: “Having taken part in Novavax’s vaccine trial myself, I am particularly thrilled to see such positive results. I want to thank the thousands of trial volunteers, without whom these results would not have been possible.
“It will now be for the regulator to do its crucial work in assessing the efficacy and safety of this vaccine, but if approved it will be a further boost to our vaccination programme.”